BioCryst US Sales Co., LLC
$658.2K 6,409 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Xtant Medical Inc
Xtant Medical Inc reported $659,264.28 across General Payments, Research, and Ownership to 454 physicians and teaching hospitals across 454 transactions.
- $659.3K
- All-tracks total
- 454
- Transactions
- 454
- Recipients
- +$400.0K
- General Payments vs PY2023
Xtant Medical Inc reported $659,264.28 across all CMS Open Payments tracks (General + Research + Ownership) to 454 physicians and teaching hospitals in Program Year 2024 - ranking #704 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $659,264.28, averaging $1.5K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer xtant-medical-inc Xtant Medical Inc
$659.3K · #704/1,925 · 0.0% industry · PY2024
- TOT $659.3K
- RANK #704
- SHARE 0.0%
- TXN 454
- RCP 454
- CAT 4
- GEN $659.3K
- ΔGEN +$400.0K
- TOP1 16.7%
- PY 2024
Volume peers
Nearest volume peer: BioCryst US Sales Co., LLC ($658.2K)
Xtant Medical Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Xtant Medical Inc's CMS-reported General Payments increased by $400.0K (+154.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: XTANT MEDICAL INCPY2023: XTANT MEDICAL INCPY2024: XTANT MEDICAL INC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $259,295.33
- PY2024
- $659,264.28
What the Data Shows for Xtant Medical Inc
$659,264.28: that is what Xtant Medical Inc reported in payments to 454 physicians and teaching hospitals during Program Year 2024, spread across 454 transactions ($1.5K per transaction, $1.5K per recipient). The company sits at rank #704 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $476.6K, accounting for 72.3% of this company's General Payments and 116 transactions.
General Payment Breakdown by Type
Xtant Medical Inc made 4 types of general payments. "Consulting Fee" is the largest category at $476.6K, 72.3% of General Payments.
Xtant Medical Inc reports 4 general-payment categories - the top three are Consulting Fee (72.3%), Royalty or License (18.7%), and Travel and Lodging (5.5%). The remaining 1 category make up 3.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Xtant Medical Inc divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $476.6K | 116 | 72.3% |
| Royalty or License | $123.4K | 83 | 18.7% |
| Travel and Lodging | $36.4K | 18 | 5.5% |
| Food and Beverage | $22.8K | 237 | 3.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $329,830.77 (50.0%) of $659,264.28 in this company's General Payments records across 176 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Xtant Medical Inc
The five named recipients with the highest reported General Payments from this company
- 1
Duke Oscar Kasprisin
$109,869.28 across 14 reported transactions
- 2
Kenneth Conger
$77,949.46 across 13 reported transactions
- 3
Sally Fathi Alrabaa
$57,250.00 across 4 reported transactions
- 4
Peter Herbert Cherouny
$51,254.76 across 13 reported transactions
- 5
David John Yeh
$33,507.27 across 31 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Xtant Medical Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Xtant Medical Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Xtant Medical Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Enterra Medical, Inc.
$656.0K 1,810 recipients
Compare payment profiles
Fusion Orthopedics USA, LLC
$655.1K 780 recipients
Compare payment profiles
Seigla Medical, Inc.
$651.1K 12 recipients
Compare payment profiles
Vascular Graft Solutions Inc
$668.1K 2 recipients
Compare payment profiles
Aesculap Implant Systems, LLC
$670.4K 222 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.